2025 NICA Annual Conference

June 20 - 21

//

Miami Beach, FL.

October 10, 2024

Access Issues, Emergency Resources, Operations, Risk Management

As the voice for all infusion providers across the nation, NICA has new guidance on preparing for and navigating potential disruptions to supply distribution or supply […]

December 26, 2024

Operations

The current standard of care around IV monitoring is to “wait and see” if an injury occurs. This is simply not acceptable – especially in cases […]

December 13, 2024

Operations

Unlock the full potential of your infusion center by expanding beyond your specialty—offering diverse therapies to increase patient access, enhance community impact, and boost your practice’s […]

September 24, 2024

Legal, Operations, Risk Management

The Corporate Practice of Medicine (“CPOM”) doctrine is one of the relatively significant legal issues to consider for corporate entities seeking to provide healthcare services.

August 5, 2024

Operations, Providers

By: Patrick LaVoie, CEO and Founder of Thrivory, Inc. Navigating Financial Options to Improve Your Infusion Center’s Performance Infusion centers play a vital role in the […]

June 27, 2024

Operations, Providers, Risk Management, Training

Infusion providers focused on providing excellent patient care often ask themselves, “How do I design a clinical training program that focuses on clinician competency and excellent patient care?”

February 20, 2024

Billing, Operations, Providers, Risk Management

By: Tiffani Bouchard, CCS Managing JW and JZ Modifiers When Billing Single-Dose Drugs Managing JW and JZ modifiers when billing single-dose drugs can be challenging. As […]

January 30, 2024

Operations, Pharmacology, Providers, Risk Management

By: Pamela McIntyre, CRNI, IgCN, OCN, and VA-BC Maximizing Efficiency in Ambulatory Infusion Centers When it comes to maximizing efficiency in ambulatory infusion centers, one of […]

August 22, 2023

Operations, Pharmacology, Providers, Risk Management

By: Michael Rigas, Pharm.D., FNHIA Biosimilars are also known as follow-on biologics or subsequent-entry biologics. They are FDA-approved copies of the original “innovator” drug product that […]

NICA